Goldman Sachs joins Ikonisys' series E:
This article was originally published in Clinica
Ikonisys, a developer of cell-based diagnostic products, has secured $30m in a series E round. The financing came from existing shareholders in the New Haven, Connecticut firm and from new investor Goldman Sachs. The funds will enable Ikonisys to achieve further clinical milestones and launch new tests within its oncoFISH and fastFISH product lines. The oncoFISH portfolio focuses on cancer diagnostics, while the fastFISH line is dedicated to the prenatal detection of genetic disorders - both are designed to run on the Ikoniscope robotic digital microscopy platform. The company expects to launch the first two rare cell detection tests in 2008.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.